Moderna Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on February 14, 2025, analysts are closely watching its financial performance. Moderna's competitors include Pfizer and BioNTech, which also focus on mRNA-based vaccines.
Wall Street analysts estimate Moderna's earnings per share (EPS) to be -$2.86 for the quarter. However, recent projections suggest a slightly better outcome, with an expected loss of $2.65 per share. This marks a significant decline of 581.8% compared to the previous year. Despite this, there has been a 7.2% upward revision in the consensus EPS estimate over the past 30 days, as highlighted by Zacks Investment Research.
Revenue for the quarter is projected to be approximately $941 million, with some estimates slightly higher at $956 million. This represents a 66% decrease from the same quarter last year. A significant portion of Moderna's revenue is expected to come from its COVID-19 vaccine, with sales estimated at $869 million. The decline in revenue is attributed to reduced demand for the vaccine.
Moderna's financial ratios provide insight into its current situation. The company has a negative price-to-earnings (P/E) ratio of -5.29, indicating negative earnings. The price-to-sales ratio is about 2.31, suggesting investors are willing to pay $2.31 for every dollar of sales. Despite negative earnings, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.
Investors will be keen to hear updates on Moderna's pipeline during the earnings report. The company's RSV vaccine, mResvia, which received FDA approval in May, is expected to contribute minimally to sales. The management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations.
